Assembly Biosciences (ASMB) 7.32 $ASMB Assembly
Post# of 273242
Posted On: 09/21/2016 5:01:42 AM
Assembly Biosciences (ASMB) 7.32 $ASMB
Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated with the human microbiome, announced that President and CEO Derek Small will present at the Jefferies 2016 Global Healthcare Conference in New York City. The presentation is scheduled for Tuesday, June 7, 2016 at 10:30 AM EDT. A Question and Answer session will follow the presentation.
ASMB: 7.32 (+0.16)
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
GlobeNewswire - Wed Apr 13, 6:00AM CDT
--In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties--
ASMB: 7.32 (+0.16)
Microbiome Therapeutics Market, 2015 - 2030: Imbalance in the Natural Microbiota are a Known Cause for Many Chronic Diseases
M2 - Tue Feb 02, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5c5n6/microbiome) has announced the addition of the "Microbiome Therapeutics Market, 2015 - 2030" report to their offering. In addition to the existing treatment plans for certain health conditions, approaches that modify natural formulations by adding or removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. Using microbiome as a therapy has unique advantages over traditional small molecules or biologics. It can be used to identify individual therapeutic microorganisms and help in designing the therapies customized to the patient's microbiome. Unlike the adverse effects posed by the prolonged use of drugs such as the antibiotics, microbiome therapeutics have a lower risk of toxicity associated with them. In addition, microbiome based therapies provide a rich source of new biomarkers helping in the classification of the patients into relatively homogeneous sub-populations. Currently, there are many popular probiotics, prebiotics, medical food and supplements commercially available in the market as OTC products. These products are known to prevent a number of diseases by restoring the human microbiome to its natural state. However, these products cannot be used as a replacement for medication or as a treatment for the eradication of the disease. The overall microbiome therapeutics market is still in its infancy with no approved drugs; Faecal microbial transplant (FMT) is the only microbiome related therapy that has entered the market. With several firms and investors displaying a growing interest in this field, the overall market holds a strong potential in the coming years. Companies Mentioned: - 4D Pharma - AOBiome - APC Microbiome Institute - AbbVie - ActoGeniX - Admera Health - Advanced Technology Ventures - Advancing Bio - AgBiome - Assembly Biosciences - Avid Biotics - Azitra - BTER Foundation - Baylor College of Medicine - Beth Israel Deaconess Medical Center - Defence Advanced Research Projects Agency (DARPA) - Dermala - Duke University - Enso Ventures - Enterologics - Enterome BioScience - Epibiome - Monarch Labs - Monash University - MonterFiore Medical Research Center of Connecticut - Morgenthaler - Quorum Innovations - Symbiotix Biotherapies - Synlogic - Synthetic Biologics - (130 More) Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Microbiome Therapeutics And Diagnostics: Market Landscape 5. Probiotic And Prebiotic Drugs 6. Key Therapeutic Areas 7. Venture Capital Interest 8. Recent Collaborations 9. Market Sizing And Opportunity Analysis 10. Company Profiles 11. Conclusion 12. Interview Transcripts For more information visit http://www.researchandmarkets.com/research/n5c5n6/microbiome
SYN: 1.70 (-0.01), ASMB: 7.32 (+0.16)
Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
GlobeNewswire - Wed Jan 27, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI), today reported that Mohan Kabadi, PhD, Assembly's Vice President of Pharmaceutical Development, presented Gemicel proof of principle data at the 5th Drug Formulation, Solubility & Bioavailability Summit. Gemicel is a patent pending enabling platform technology that allows for targeted oral delivery of live biotherapeutics, vaccines, complex macromolecules and small molecules to specific regions of the gastrointestinal (GI) tract.
ASMB: 7.32 (+0.16)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 12.00 (-0.11), ABUS: 3.84 (+0.11), BSPM: 3.80 (+0.90), CMRX: 5.86 (+0.32), CVM: 0.42 (-0.02), ARWR: 7.36 (+0.28), ASMB: 7.32 (+0.16)
Assembly Biosciences Expands Senior Leadership Team
GlobeNewswire - Mon Jan 11, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the organization. The added team members include Richard Colonno, PhD, as Chief Scientific Officer; Thomas Rollins as Chief Development Officer and Head of the Microbiome Program; Elizabeth Haber Lacy as General Counsel and Vice President of Legal Operations; Wayne Herber, PhD, as Vice President, Biological Manufacturing and Quality; Hongmei Huang, PhD, as Vice President, Information Technology and Informatics; Leping Li, PhD, as Vice President, Discovery; Micah Mackison as Vice President, Corporate Development and Strategy; Eric Ruby as Vice President, Regulatory Affairs and Quality Assurance and Simon Haydar, PhD, as Senior Director, Discovery.
ASMB: 7.32 (+0.16)
Assembly Biosciences names Alan J. Lewis PhD to board
M2 - Tue Dec 22, 3:05AM CST
Biotechnology company Assembly Biosciences (NasdaqCM:ASMB) disclosed on Monday that it has appointed Alan J. Lewis, PhD to its board of directors.
ASMB: 7.32 (+0.16)
Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors
GlobeNewswire - Mon Dec 21, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced the appointment of Alan J. Lewis, PhD, to the company's board of directors. Dr. Lewis has had a distinguished career in senior management and research & development roles in the pharmaceutical and biotechnology industry for more than 30 years.
ASMB: 7.32 (+0.16)
Assembly Biosciences to Present at Jefferies Microbiome Summit
GlobeNewswire - Wed Dec 16, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participate in the Jefferies Microbiome Summit being held today in Boston, MA. Uri Lopatin, MD, Assembly's Chief Medical Officer, will present an overview of the company's microbiome program.
ASMB: 7.32 (+0.16)
Clinical Study Shows Assembly Biosciences' Oral Gemicel(TM) Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
GlobeNewswire - Wed Dec 09, 6:00AM CST
--Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases--
ASMB: 7.32 (+0.16)
Diarrhea - Pipeline Review, H2 2015
M2 - Tue Dec 08, 3:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ns6wck/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diarrhea. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Aegis Therapeutics, LLC - Akthelia pharmaceuticals ehf - Allergan Plc - Anatara Lifesciences Limited - Ardelyx, Inc. - Assembly Biosciences, Inc. - Chiesi Farmaceutici SpA - Chongqing Zhifei Biological Products Co., Ltd. - Cosmo Pharmaceuticals S.p.A - DesignMedix, Inc. - DiscoveryBiomed, Inc. - GlaxoSmithKline Plc - GP Pharm, S.A. - Helsinn Healthcare S.A. - Intercept Pharmaceuticals, Inc. - Ipsen S.A. - Merck & Co., Inc. - Mucosis B.V. - Nippon Shinyaku Co., Ltd. - Novartis AG - Pfizer Inc. - Prokarium Limited - Protagonist Therapeutics Inc. - Rebiotix Inc. - Sanofi Pasteur SA - Scandinavian Biopharma Holding AB - Shire Plc - Sigmoid Pharma Limited - Summit Therapeutics Plc - Synthetic Biologics, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/ns6wck/diarrhea
AGN: 238.67 (-6.62), SYN: 1.70 (-0.01), SHPG: 206.56 (+3.12), PFE: 33.81 (+0.16), MRK: 61.94 (+0.61), ICPT: 170.01 (+13.27), ASMB: 7.32 (+0.16), GSK: 43.06 (-0.24), NVS: 81.06 (+1.12)
Trading Ahead of Upcoming Developments - Research on Assembly Biosciences, Integrated Electrical Services, Rosetta Stone and Rightside Group
ACCESSWIRE - Mon Nov 30, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Assembly Biosciences Inc. (NASDAQ: ASMB), Integrated Electrical Services Inc. (NASDAQ: IESC), Rosetta Stone Inc. (NYSE: RST) and Rightside Group Ltd (NASDAQ: NAME). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NAME: 8.55 (+0.30), IESC: 15.73 (-0.38), ASMB: 7.32 (+0.16), RST: 7.96 (-0.23)
Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
GlobeNewswire - Tue Oct 06, 6:00AM CDT
--Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies--
ASMB: 7.32 (+0.16)
Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015.
BIOS: 2.87 (-0.05), ASMB: 7.32 (+0.16)
BUYINS.NET: ASMB SqueezeTrigger Price is $13.65. There is $8,805,816 That Short Sellers Still Need To Cover.
M2 - Thu Sep 17, 3:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARISTA MLS CO (NASDAQ:ASMB) in real time and just received an alert that ASMB is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 643700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $13.65. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ASMB: 7.32 (+0.16)
BUYINS.NET: ASMB SqueezeTrigger Price is $13.65. There is $7,781,184 That Short Sellers Still Need To Cover.
M2 - Wed Sep 09, 3:31AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARISTA MLS CO (NASDAQ:ASMB) in real time and just received an alert that ASMB is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 568800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $13.65. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ASMB: 7.32 (+0.16)
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 12.00 (-0.11), BSPM: 3.80 (+0.90), CMRX: 5.86 (+0.32), ARWR: 7.36 (+0.28), ASMB: 7.32 (+0.16)
Global Hemorrhoid Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Tue Aug 11, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rk4tpc/hemorrhoids) has announced the addition of the "Hemorrhoids Global Clinical Trials Review, H1, 2015" report to their offering. Summary Our clinical trial report, Hemorrhoids Global Clinical Trials Review, H1, 2015" provides data on the Hemorrhoids clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemorrhoids. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemorrhoids. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Clinical Trial Overview of Top Companies - Panacea Biotec Limited - Pharmafar S.r.l. - Peritech Pharma - Pacira Pharmaceuticals, Inc. - Dr. Kade Pharmazeutische Fabrik GmbH - Chemische Fabrik Kreussler & Co. GmbH - Assembly Biosciences, Inc. - G&W Laboratories, Inc. - Arjun Healthcare - Abbott Laboratories Clinical Trial Overview of Top Institutes / Government - Mazandaran University of Medical Sciences - Center for Genetic Engineering and Biotechnology - Central Council for Research in Ayurvedic Sciences - Hospital de Clinicas de Porto Alegre - Shiraz University of Medical Sciences - Sun Yat-sen University - University of California, Los Angeles - Akershus University Hospital - APMC College of Pharmaceutical Education & Research - Asker & Baerum Hospital For more information visit http://www.researchandmarkets.com/research/rk...emorrhoids
ABT: 41.58 (-0.10), ASMB: 7.32 (+0.16), PCRX: 40.37 (-0.74)
Anal Fissure - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tmwssr/anal_fissure) has announced the addition of the "Anal Fissure Global Clinical Trials Review, H1, 2015" report to their offering. "Anal Fissure Global Clinical Trials Review, H1, 2015" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Anal Fissure Therapeutics Clinical Trials - S.L.A. Pharma AG - Assembly Biosciences, Inc. - Troikaa Pharmaceuticals Ltd. - RDD Pharma Ltd. - SOFAR S.p.A. - Ipsen S.A. - Kyowa Hakko Kirin Co., Ltd. - Forest Laboratories, Inc. - Actavis plc - Abbott Laboratories - Mazandaran University of Medical Sciences - Agostino Gemelli University Polyclinic - Ankara University - Bispebjerg Hospital - Bushehr University of Medical Sciences - Elche University General Hospital - Hadassah Medical Organization - Hamedan University of Medical Sciences - Hospital del Mar - Hospital Universitario Reina Sofia For more information visit http://www.researchandmarkets.com/research/tm...al_fissure
ABT: 41.58 (-0.10), ASMB: 7.32 (+0.16)
Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated with the human microbiome, announced that President and CEO Derek Small will present at the Jefferies 2016 Global Healthcare Conference in New York City. The presentation is scheduled for Tuesday, June 7, 2016 at 10:30 AM EDT. A Question and Answer session will follow the presentation.
ASMB: 7.32 (+0.16)
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
GlobeNewswire - Wed Apr 13, 6:00AM CDT
--In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties--
ASMB: 7.32 (+0.16)
Microbiome Therapeutics Market, 2015 - 2030: Imbalance in the Natural Microbiota are a Known Cause for Many Chronic Diseases
M2 - Tue Feb 02, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5c5n6/microbiome) has announced the addition of the "Microbiome Therapeutics Market, 2015 - 2030" report to their offering. In addition to the existing treatment plans for certain health conditions, approaches that modify natural formulations by adding or removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. Using microbiome as a therapy has unique advantages over traditional small molecules or biologics. It can be used to identify individual therapeutic microorganisms and help in designing the therapies customized to the patient's microbiome. Unlike the adverse effects posed by the prolonged use of drugs such as the antibiotics, microbiome therapeutics have a lower risk of toxicity associated with them. In addition, microbiome based therapies provide a rich source of new biomarkers helping in the classification of the patients into relatively homogeneous sub-populations. Currently, there are many popular probiotics, prebiotics, medical food and supplements commercially available in the market as OTC products. These products are known to prevent a number of diseases by restoring the human microbiome to its natural state. However, these products cannot be used as a replacement for medication or as a treatment for the eradication of the disease. The overall microbiome therapeutics market is still in its infancy with no approved drugs; Faecal microbial transplant (FMT) is the only microbiome related therapy that has entered the market. With several firms and investors displaying a growing interest in this field, the overall market holds a strong potential in the coming years. Companies Mentioned: - 4D Pharma - AOBiome - APC Microbiome Institute - AbbVie - ActoGeniX - Admera Health - Advanced Technology Ventures - Advancing Bio - AgBiome - Assembly Biosciences - Avid Biotics - Azitra - BTER Foundation - Baylor College of Medicine - Beth Israel Deaconess Medical Center - Defence Advanced Research Projects Agency (DARPA) - Dermala - Duke University - Enso Ventures - Enterologics - Enterome BioScience - Epibiome - Monarch Labs - Monash University - MonterFiore Medical Research Center of Connecticut - Morgenthaler - Quorum Innovations - Symbiotix Biotherapies - Synlogic - Synthetic Biologics - (130 More) Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Microbiome Therapeutics And Diagnostics: Market Landscape 5. Probiotic And Prebiotic Drugs 6. Key Therapeutic Areas 7. Venture Capital Interest 8. Recent Collaborations 9. Market Sizing And Opportunity Analysis 10. Company Profiles 11. Conclusion 12. Interview Transcripts For more information visit http://www.researchandmarkets.com/research/n5c5n6/microbiome
SYN: 1.70 (-0.01), ASMB: 7.32 (+0.16)
Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
GlobeNewswire - Wed Jan 27, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI), today reported that Mohan Kabadi, PhD, Assembly's Vice President of Pharmaceutical Development, presented Gemicel proof of principle data at the 5th Drug Formulation, Solubility & Bioavailability Summit. Gemicel is a patent pending enabling platform technology that allows for targeted oral delivery of live biotherapeutics, vaccines, complex macromolecules and small molecules to specific regions of the gastrointestinal (GI) tract.
ASMB: 7.32 (+0.16)
World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 12.00 (-0.11), ABUS: 3.84 (+0.11), BSPM: 3.80 (+0.90), CMRX: 5.86 (+0.32), CVM: 0.42 (-0.02), ARWR: 7.36 (+0.28), ASMB: 7.32 (+0.16)
Assembly Biosciences Expands Senior Leadership Team
GlobeNewswire - Mon Jan 11, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the organization. The added team members include Richard Colonno, PhD, as Chief Scientific Officer; Thomas Rollins as Chief Development Officer and Head of the Microbiome Program; Elizabeth Haber Lacy as General Counsel and Vice President of Legal Operations; Wayne Herber, PhD, as Vice President, Biological Manufacturing and Quality; Hongmei Huang, PhD, as Vice President, Information Technology and Informatics; Leping Li, PhD, as Vice President, Discovery; Micah Mackison as Vice President, Corporate Development and Strategy; Eric Ruby as Vice President, Regulatory Affairs and Quality Assurance and Simon Haydar, PhD, as Senior Director, Discovery.
ASMB: 7.32 (+0.16)
Assembly Biosciences names Alan J. Lewis PhD to board
M2 - Tue Dec 22, 3:05AM CST
Biotechnology company Assembly Biosciences (NasdaqCM:ASMB) disclosed on Monday that it has appointed Alan J. Lewis, PhD to its board of directors.
ASMB: 7.32 (+0.16)
Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors
GlobeNewswire - Mon Dec 21, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced the appointment of Alan J. Lewis, PhD, to the company's board of directors. Dr. Lewis has had a distinguished career in senior management and research & development roles in the pharmaceutical and biotechnology industry for more than 30 years.
ASMB: 7.32 (+0.16)
Assembly Biosciences to Present at Jefferies Microbiome Summit
GlobeNewswire - Wed Dec 16, 6:30AM CST
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participate in the Jefferies Microbiome Summit being held today in Boston, MA. Uri Lopatin, MD, Assembly's Chief Medical Officer, will present an overview of the company's microbiome program.
ASMB: 7.32 (+0.16)
Clinical Study Shows Assembly Biosciences' Oral Gemicel(TM) Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
GlobeNewswire - Wed Dec 09, 6:00AM CST
--Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases--
ASMB: 7.32 (+0.16)
Diarrhea - Pipeline Review, H2 2015
M2 - Tue Dec 08, 3:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ns6wck/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diarrhea. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Aegis Therapeutics, LLC - Akthelia pharmaceuticals ehf - Allergan Plc - Anatara Lifesciences Limited - Ardelyx, Inc. - Assembly Biosciences, Inc. - Chiesi Farmaceutici SpA - Chongqing Zhifei Biological Products Co., Ltd. - Cosmo Pharmaceuticals S.p.A - DesignMedix, Inc. - DiscoveryBiomed, Inc. - GlaxoSmithKline Plc - GP Pharm, S.A. - Helsinn Healthcare S.A. - Intercept Pharmaceuticals, Inc. - Ipsen S.A. - Merck & Co., Inc. - Mucosis B.V. - Nippon Shinyaku Co., Ltd. - Novartis AG - Pfizer Inc. - Prokarium Limited - Protagonist Therapeutics Inc. - Rebiotix Inc. - Sanofi Pasteur SA - Scandinavian Biopharma Holding AB - Shire Plc - Sigmoid Pharma Limited - Summit Therapeutics Plc - Synthetic Biologics, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/ns6wck/diarrhea
AGN: 238.67 (-6.62), SYN: 1.70 (-0.01), SHPG: 206.56 (+3.12), PFE: 33.81 (+0.16), MRK: 61.94 (+0.61), ICPT: 170.01 (+13.27), ASMB: 7.32 (+0.16), GSK: 43.06 (-0.24), NVS: 81.06 (+1.12)
Trading Ahead of Upcoming Developments - Research on Assembly Biosciences, Integrated Electrical Services, Rosetta Stone and Rightside Group
ACCESSWIRE - Mon Nov 30, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Assembly Biosciences Inc. (NASDAQ: ASMB), Integrated Electrical Services Inc. (NASDAQ: IESC), Rosetta Stone Inc. (NYSE: RST) and Rightside Group Ltd (NASDAQ: NAME). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NAME: 8.55 (+0.30), IESC: 15.73 (-0.38), ASMB: 7.32 (+0.16), RST: 7.96 (-0.23)
Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
GlobeNewswire - Tue Oct 06, 6:00AM CDT
--Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies--
ASMB: 7.32 (+0.16)
Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015. BIOS: 2.87 (-0.05), ASMB: 7.32 (+0.16)
BUYINS.NET: ASMB SqueezeTrigger Price is $13.65. There is $8,805,816 That Short Sellers Still Need To Cover.
M2 - Thu Sep 17, 3:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARISTA MLS CO (NASDAQ:ASMB) in real time and just received an alert that ASMB is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 643700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $13.65. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ASMB: 7.32 (+0.16)
BUYINS.NET: ASMB SqueezeTrigger Price is $13.65. There is $7,781,184 That Short Sellers Still Need To Cover.
M2 - Wed Sep 09, 3:31AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARISTA MLS CO (NASDAQ:ASMB) in real time and just received an alert that ASMB is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 568800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $13.65. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ASMB: 7.32 (+0.16)
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 12.00 (-0.11), BSPM: 3.80 (+0.90), CMRX: 5.86 (+0.32), ARWR: 7.36 (+0.28), ASMB: 7.32 (+0.16)
Global Hemorrhoid Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Tue Aug 11, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rk4tpc/hemorrhoids) has announced the addition of the "Hemorrhoids Global Clinical Trials Review, H1, 2015" report to their offering. Summary Our clinical trial report, Hemorrhoids Global Clinical Trials Review, H1, 2015" provides data on the Hemorrhoids clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemorrhoids. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemorrhoids. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Clinical Trial Overview of Top Companies - Panacea Biotec Limited - Pharmafar S.r.l. - Peritech Pharma - Pacira Pharmaceuticals, Inc. - Dr. Kade Pharmazeutische Fabrik GmbH - Chemische Fabrik Kreussler & Co. GmbH - Assembly Biosciences, Inc. - G&W Laboratories, Inc. - Arjun Healthcare - Abbott Laboratories Clinical Trial Overview of Top Institutes / Government - Mazandaran University of Medical Sciences - Center for Genetic Engineering and Biotechnology - Central Council for Research in Ayurvedic Sciences - Hospital de Clinicas de Porto Alegre - Shiraz University of Medical Sciences - Sun Yat-sen University - University of California, Los Angeles - Akershus University Hospital - APMC College of Pharmaceutical Education & Research - Asker & Baerum Hospital For more information visit http://www.researchandmarkets.com/research/rk...emorrhoids
ABT: 41.58 (-0.10), ASMB: 7.32 (+0.16), PCRX: 40.37 (-0.74)
Anal Fissure - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tmwssr/anal_fissure) has announced the addition of the "Anal Fissure Global Clinical Trials Review, H1, 2015" report to their offering. "Anal Fissure Global Clinical Trials Review, H1, 2015" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Anal Fissure Therapeutics Clinical Trials - S.L.A. Pharma AG - Assembly Biosciences, Inc. - Troikaa Pharmaceuticals Ltd. - RDD Pharma Ltd. - SOFAR S.p.A. - Ipsen S.A. - Kyowa Hakko Kirin Co., Ltd. - Forest Laboratories, Inc. - Actavis plc - Abbott Laboratories - Mazandaran University of Medical Sciences - Agostino Gemelli University Polyclinic - Ankara University - Bispebjerg Hospital - Bushehr University of Medical Sciences - Elche University General Hospital - Hadassah Medical Organization - Hamedan University of Medical Sciences - Hospital del Mar - Hospital Universitario Reina Sofia For more information visit http://www.researchandmarkets.com/research/tm...al_fissure
ABT: 41.58 (-0.10), ASMB: 7.32 (+0.16)
(0)
(0)Scroll down for more posts ▼